Abstract
One promising therapeutic strategy for treating cancer is to specifically target signal transduction pathways that have a key role in oncogenic transformation and malignant progression. Hsp90 is an emerging therapeutic target of interest for the treatment of cancer. It is responsible for modulating cellular response to stress by maintaining the function of numerous signalling proteins – known as ‘client proteins’ – that are associated with cancer cell survival and proliferation. Many cancers result from specific mutations in, or aberrant expression of, these client proteins. Small molecule Hsp90 inhibitors bind to the ATP binding pocket, inhibit chaperone function and could potentially result in cytostasis or cell death. Consequently, many client proteins are targeted for degradation via the ubiquitin-proteasome pathway including receptor and non receptor kinases (Erb-B2, epidermal growth factor receptor, and Src family kinases), serine/threonine kinases (c-Raf-1 and Cdk4), steroid hormone receptors (androgen and estrogen), and apoptosis regulators such as mutant p53. Inhibition of Hsp90 function has also proven effective in killing cancer cells that have developed resistance to targeted therapies such as kinase inhibitors. This review is intended to update recent developments in new Hsp90 inhibitors as antitumors agents, the design, biological evaluation and their clinical trials studies.
Keywords: Heat shock protein 90 (Hsp90), co-chaperone (client proteins), antitumor agents, apoptosis, proteasome
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in Hsp90 Inhibitors as Antitumor Agents
Volume: 8 Issue: 7
Author(s): S. Messaoudi, J. F. Peyrat, J. D. Brion and M. Alami
Affiliation:
Keywords: Heat shock protein 90 (Hsp90), co-chaperone (client proteins), antitumor agents, apoptosis, proteasome
Abstract: One promising therapeutic strategy for treating cancer is to specifically target signal transduction pathways that have a key role in oncogenic transformation and malignant progression. Hsp90 is an emerging therapeutic target of interest for the treatment of cancer. It is responsible for modulating cellular response to stress by maintaining the function of numerous signalling proteins – known as ‘client proteins’ – that are associated with cancer cell survival and proliferation. Many cancers result from specific mutations in, or aberrant expression of, these client proteins. Small molecule Hsp90 inhibitors bind to the ATP binding pocket, inhibit chaperone function and could potentially result in cytostasis or cell death. Consequently, many client proteins are targeted for degradation via the ubiquitin-proteasome pathway including receptor and non receptor kinases (Erb-B2, epidermal growth factor receptor, and Src family kinases), serine/threonine kinases (c-Raf-1 and Cdk4), steroid hormone receptors (androgen and estrogen), and apoptosis regulators such as mutant p53. Inhibition of Hsp90 function has also proven effective in killing cancer cells that have developed resistance to targeted therapies such as kinase inhibitors. This review is intended to update recent developments in new Hsp90 inhibitors as antitumors agents, the design, biological evaluation and their clinical trials studies.
Export Options
About this article
Cite this article as:
Messaoudi S., Peyrat F. J., Brion D. J. and Alami M., Recent Advances in Hsp90 Inhibitors as Antitumor Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914824
DOI https://dx.doi.org/10.2174/187152008785914824 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Therapeutic Potential of Host Defense Peptides in Antibiotic-resistant Infections
Current Pharmaceutical Design Drug Delivery Systems For Anti-Cancer Active Complexes of Some Coinage Metals
Current Medicinal Chemistry Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy
Current Cancer Drug Targets TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design The Role of miRNAs in the Differentiation of Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine Network-based Drug Discovery, Anti-cancer Molecular Targets and Therapeutic use of Phytochemicals
Anti-Cancer Agents in Medicinal Chemistry Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Current Pharmaceutical Design Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Subject Index To Volume 2
Current Medicinal Chemistry - Anti-Cancer Agents Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers
Current Molecular Medicine Stem Cells in Adult Human Ovaries: From Female Fertility to Ovarian Cancer
Current Pharmaceutical Design Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Artificial Virus as Trump-card to Resolve Exigencies in Targeted Gene Delivery
Mini-Reviews in Medicinal Chemistry Synthesis of Mannich Bases by Two Different Methods and Evaluation of their Acetylcholine Esterase and Carbonic Anhydrase Inhibitory Activities
Letters in Drug Design & Discovery Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design